Tiziana Life Sciences Plc (“Tiziana” or the “Company”): Placing to Raise £275,000
November 27 2017 - 6:00AM
Business Wire
Tiziana Life Sciences plc (AIM: TILS), a clinical stage
biotechnology company developing targeted drugs for cancer and
autoimmune diseases, today announces that it has raised £275,000 by
the issue of 183,333 new ordinary shares (“Placing Shares”)
at a price of 150p per share, each Placing Share having a warrant
attached entitling the holder to subscribe for one new ordinary
share at an exercise price of 160p per share, exercisable until 11
December 2022 (the “Placing”).
Application has been made to the London Stock Exchange plc to
admit the Placing Shares to trading on AIM and admission is
expected to occur on 11 December 2017. The Placing Shares will rank
pari passu with the existing ordinary shares of nominal value 3p
each in the capital of the Company (the “Ordinary Shares”).
Following the issue of the Placing Shares, the enlarged issued
share capital of the Company will comprise 124,111,271 Ordinary
Shares.
The Company has granted options over a total of 10,149,403
Ordinary Shares of which 4,752,500 are vested at exercise
prices between 15p and £1.25p per share and 5,396,903 remain
subject to vesting conditions (at potential exercise prices ranging
from 15p to £1.925 per share). In addition warrants to subscribe
for a total of 4,522,912 Ordinary Shares at exercise prices between
50p and £2.50 are outstanding, including the new warrants granted
in the Placing.
Therefore the fully diluted issued share capital of the Company
is 138,783,586 Ordinary Shares (assuming all options and warrants,
vested and unvested, exercised and exercisable, were
converted).
In conformity with DTR 5.6.1, the Company notifies that as at
the date of this announcement, it has a single class of shares in
issue being Ordinary Shares and that following the issue of the
Placing Shares, the total number of Ordinary Shares in issue will
be 124,111,271. There are no Ordinary Shares held in Treasury. Each
Ordinary Share entitles the holder to a single vote at general
meetings of the Company.
This figure of 124,111,271 Ordinary Shares may be used by
shareholders (and others with notification obligations) as the
denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure
Guidance and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
About Tiziana
Tiziana is a UK biotechnology company that focuses on the
discovery and development of novel molecules that treat human
disease in oncology and immunology. The Company is focused on its
lead compound milciclib. The Company is also in clinical
development of foralumab. Foralumab is the only fully human
engineered human anti-CD3 antibody in clinical development. This
phase II compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBS),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
inflammatory bowel disease (IBD), psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
For more information go to
http://www.tizianalifesciences.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171127005416/en/
Tiziana Life Sciences plcGabriele Cerrone, Chairman and
founder+44 (0)20 7493 2853orCairn Financial Advisers LLP
(Nominated adviser)Liam Murray / Jo Turner+44 (0)20 7213
0880orBeaufort Securities Limited (Broker)Elliot Hance+44
(0)20 7382 8300orFTI ConsultingSimon Conway / Natalie
Garland-Collins+44 (0)20 3727 1000
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024